Parkinson’s-adapted cognitive stimulation therapy: feasibility and acceptability in Lewy body spectrum disorders
Sheree A. McCormick(Manchester Academic Health Science Centre), Iracema Leroi(Trinity College Dublin), Benjamin Kwapong(University of Manchester), Tarek Abdel-Ghany(North West Boroughs Healthcare NHS Foundation Trust), Jason Raw(Pennine Acute Hospitals NHS Trust), David Ahearn(Wythenshawe Hospital), Christine Taylor, Lesley‐Anne Carter(Manchester Academic Health Science Centre), Sarah Smith(Leeds Beckett University), Sabina Vatter(Greater Manchester Mental Health NHS Foundation Trust), Ellen Poliakoff(University of Manchester), Vasiliki Orgeta(Faculty (United Kingdom)), Joanne Rodda(North East London NHS Foundation Trust), Monty Silverdale(Salford Royal NHS Foundation Trust)
Cited by 37
Related Papers
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
|The Lancet Neurology|2009|460
Cognitive Impairment in Parkinson Disease
|Journal of Geriatric Psychiatry and Neurology|2012|380
Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
|International Journal of Geriatric Psychiatry|2004|228
Neuropsychiatry of Huntington’s Disease and Other Basal Ganglia Disorders
|Psychosomatics|2000|223
Impact of the COVID-19 Pandemic on Loneliness and Social Isolation: A Multi-Country Study
|International Journal of Environmental Research and Public Health|2021|208